The level of peripheral blood circulating CD34+ cells is higher in acute promyelocytic leukemia patients with adverse prognostic factors

Figures & data

Figure 1 Each circle or square or triangle represents one study and the bars represent the median count of each subgroup. APL compared with normal, P = 0.020; high compared with intermediate-low, P = 0.005; intermediate-low compared with normal, P = 0.613; high compared with normal P < 0.001.

Figure 2 Each circle or filled circle represents one study. Circle represents poor clinical indexes, respectively, WBCs count >10 × 10⁹/l, FLT3-ITD positive mutation, PML/RARa gene complex fusion, Myelofibrosis and marrow necrosis, Chemotherapy-related APL, CD56/CD34 antigen positive expression, non-classical chromosomal translocation

Table 1 Clinical characteristics of 15 APL patients with elevated CD34+ cell counts

Patients (No)	WBCs counts	karyotype abnormality	CD56/CD34 antigen expression	FLT3-ITD mutation	PML/RARa gene complex fusion	Other indexes	CD34+cells percent (%)/absolute counts (×10^6/l)	Subgroup	Survival (months)
No. 1	5.8	Classical chromosomal translocation	CD34+ CD56+	+	−	Myelofibrosis and marrow necrosis	54.1/3031.3	Intermediate- risk	0.5
No.2	8.6	46, Y,Xp+,?t(2;9)(q34;q21), 13 p+, t(15;17)(q22; q12)[10]	CD34+ CD56−	−	+	−	60.36/5130.6	Intermediate- risk	8
No. 3	21.6	46 ,XY[6]	−	−	−	−	6.25/ 1362.5	High-risk	0.5
No. 4	58.7	47, XY, +8, t(15; 17)(q22; q12)[3]	−	−	−	−	0.03/18.66	High-risk	25
No. 5	60.2	45, X,-X,9q-,?t (11;21) (p13;q22), t(15;17)(q22;q12)[8]/46 ,XX[2]	−	−	−	−	2.83/1823.3	High-risk	33
No .6	3.5	47, XY, +8,t(15; 17)(q22; q12)[8]	−	−	−	−	4.02/140.7	Intermediate- risk	31
No .7	22.2	Classical chromosomal translocation	−	+	−	Chemotherapy-related APL	18.6/4133.6	High-risk	18
No. 8	20.2	Unsuccess	−	−	−	−	0.08/15.76	High-risk	27
No. 9	20.3	Classical chromosomal translocation	−	−	−	−	0.05/20.5	High-risk	39
No. 10	13.9	Unsuccess	−	−	−	−	0.03/18.07	High-risk	23
No. 11	43.7	47, XY,2q+,6q+,t(15;17)(q22;q12),+21[4]/49,XY,idem,+mar 1,+mar 2[2]	−	−	−	−	7.41/3238.17	High-risk	20
No. 12	1.2	Classical chromosomal translocation	CD34− CD56+	−	−	−	3.59/43.08	Intermediate- risk	18
No. 13	1.1	46, XX,3p-,-12,t(15,17)(q22;q12),+mar[6]/46,XX[4]	–	−	−	−	1.02/10.2	Intermediate- risk	10
No. 14	0.9	Classical chromosomal translocation	CD34+ CD56−	+	−	−	13.92/125.28	Intermediate- risk	7
No. 15	0.6	46, XX, t(7;19)(q21;q13), t(15;17)(q22;q12)[10]	−	+	−	−	9.99/59.94	Intermediate- risk	5

Figure 3 Log-rank tests revealed a significant difference between subgroups according to CD34+ cell absolute count (P = 0.006).

Zeng H, Zhang QG, OuYang J, Xu JY, Li P, Guan CY, et al. Analysis of circulating CD34+ cells in the peripheral blood in pancytopenia. Chin J Clin (Electron Ed) 2013;7(11):5071–3.

 Google Scholar

Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, et al. Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT. Bone Marrow Transplant  2012;47(1):143–5. doi: 10.1038/bmt.2011.17

 PubMed Web of Science ®Google Scholar

Chicha L, Feki A, Boni A, Irion O, Hovatta O, Jaconi M. Human pluripotent stem cells differentiated in fully defined medium generate hematopoietic CD34– and CD34+ progenitors with distinct characteristics. PLoS One. 2011;6(2):e14733. doi: 10.1371/journal.pone.0014733

 PubMed Web of Science ®Google Scholar

Fuchigami K, Mori H, Matsuo T, Iwanaga M, Nagai K, Kuriyama K, et al. Absolute number of circulating CD34 cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. Leuk Res 2000;24(2):163–74. doi: 10.1016/S0145-2126(99)00167-8

 PubMed Web of Science ®Google Scholar

Wagner-Souza K, Diamond HR, Ornellas MH, Gomes BE, Almeida-Oliveira A, Abdelhay E, et al. Rhodamine 123 efflux in human subpopulations of hematopoietic stem cells: comparison between bone marrow, umbilical cord blood and mobilized peripheral blood CD34+ cells. Int J Mol Med 2008;22(2):237–42.

 PubMed Web of Science ®Google Scholar

Guan CY, Zhang QG, OuYang J, Zhou RF, Zeng H, Li P, et al. The clinical significance of circulating CD34+ cells in myelodysplastic syndrome and acute leukemia. Acta Universitatis Medicinalis Nanjing (Natural Science) 2010;30(6):847–49.

 Google Scholar